There have been many advances in treatments for prostate cancer. A variety of treatment options are available, including hormonal and chemotherapeutic approaches. There is also not yet a single preferred treatment option in which all patients can be treated successfully. Although prostate cancer remains an incurable disease, recent research has led to improvements in patient care.
Men with Gleason 6-7 [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) have a higher chance of being treated with radical prostatectomy than men with Gleason 8-10 disease. From our data we conclude that there is little difference between the rates at which prostate cancer progresses in patients who are treated with radical prostatectomy vs. those who receive watchful waiting. However, when only patients with Gleason 9-10 disease are considered, patients with Gleason 8-9 disease have a significantly shorter time until recurrence than patients with Gleason 10-11 disease (p<0.01). This suggests that more aggressive treatment should be considered before radical prostatectomy rather than just watchful waiting when treating patients with Gleason 9-10 disease.
A familial predisposition towards prostate cancer was demonstrated only among men who were diagnosed with prostate cancer <or =64 years before the onset of the first case; these results are consistent with the hypothesis that prostate cancers do not arise independently during lifetime. Further genetic factors might exist but must await confirmation in large population-based studies.
The most serious complication of prostate cancer is BPH. Complications are more common among older men than younger ones but have less impact on survival. There is no clear relationship between the severity of complications and survival.
Men with RP generally have more than one motivation to seek treatment. Risk factors for prostate cancer are well known, but we did not find any strong indication of whether pathology was responsible for the occurrence of disease in most cases. We conclude that disease etiology is insignificant to prostate cancer pathogenesis, and that it cannot explain why some men develop the disease and others do not.
The data supports the theory that the procedure decreases the size and volume of the prostate, thus reducing the burden on the bladder neck and improving urine flow. This may be accomplished by relieving pressure on the urethra and relieving spasms of the muscles around the urethra.
We found that tulsa surgery was typically combined with post-operative radiation therapy, chemotherapy, hormonal therapy, surgical ablation, laser vaporization, and cryosurgery. Recent findings are similar to those reported by others in the literature.
Results from a recent clinical trial demonstrates that patients undergoing a tulsa procedure have a significantly higher chance of having positive (biopsy proven) prostate cancer than patients who receive a watchful waiting strategy. Results from a recent clinical trial support the need for more aggressive prostate cancer detection techniques to obtain a reliable cure rate when treating these patients.
A well-established medical history, physical examination, and laboratory tests are essential components of the workup of men presenting with symptoms of lower urinary tract symptoms suggestive of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). These include a complete evaluation of the bladder, urethra, and penis for evidence of suspicious lesions and/or inflammation; measurement of serum PSA and DRE at time of presentation; testicular ultrasonography; and measurement of prostate-specific antigen (PSA) in the urine. DRE, especially a palpable abnormality, is the only potentially curable indicator of prostate cancer and should be performed. The American Urological Association recommends performing a digital rectal exam within 3 months of completion of PSA testing.
Consideration of clinical trial eligibility criteria may improve enrollment rates in clinical trials. Most prostate cancer clinical trials are open to all eligible patients; however, some trials require that patients undergo prior counseling regarding possible treatment side effects. Results from a recent paper suggests that clinical trial eligibility criteria should include consideration of side effect concerns and overall health status.
Men with a first degree relative with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) have an increased risk of developing the disease themselves. The risk increases with number of affected relatives. This suggests that genetic factors play an important role in prostate development.